What is the difference between Alogliptin And Pioglitazone and Pioglitazone Hydrochloride?

Alogliptin And Pioglitazone and Pioglitazone Hydrochloride are both Thiazolidinediones, so they work through the same broad mechanism. They differ in dosing, half-life, side-effect frequency, and how individual patients tolerate them. See the head-to-head sections below for the specifics.

Is Alogliptin And Pioglitazone the same as Pioglitazone Hydrochloride?

No. Alogliptin And Pioglitazone (Alogliptin And Pioglitazone) and Pioglitazone Hydrochloride (Pioglitazone Hydrochloride) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, Alogliptin And Pioglitazone or Pioglitazone Hydrochloride?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from Alogliptin And Pioglitazone to Pioglitazone Hydrochloride?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

Alogliptin And Pioglitazone vs Pioglitazone Hydrochloride

Compare Alogliptin And Pioglitazone (Thiazolidinedione) and Pioglitazone Hydrochloride (Pioglitazone Hydrochloride), clinical data, side effects, and patient experiences.

Alogliptin And Pioglitazone

· Thiazolidinedione

How it works

12.1 Mechanism of Action OSENI combines two antihyperglycemic agents: alogliptin and pioglitazone. Alogliptin Increased concentrations of the incretin hormones such as glucagon-lik...

Approved for

1 INDICATIONS AND USAGE OSENI is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. OSENI is a combination of alogliptin

a dipeptidyl peptidase-4 inhibitor

and pioglitazone

a thiazolidinedione agonist of peroxisome proliferator receptor gamma

OralTablet

Pioglitazone Hydrochloride

Pioglitazone Hydrochloride · Thiazolidinedione

How it works

12.1 Mechanism of Action Pioglitazone is a thiazolidinedione that depends on the presence of insulin for its mechanism of action. Pioglitazone decreases insulin resistance in the p...

Approved for

14) Important Limitations of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. ( 1 )

OralTablet

Quick Comparison

Alogliptin And PioglitazonePioglitazone Hydrochloride

Drug Class

Thiazolidinedione

Route

Oral

Half-Life

N/A

FDA Approved

N/A

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

Alogliptin And Pioglitazone

Diarrhea

1-10%

Nausea

1-10%

Vomiting

1-10%

Rash

1-10%

General Unwellness

1-10%

Shortness of Breath

1-10%

Drug Not Working

1-10%

Dizziness

1-10%

Pioglitazone Hydrochloride

Nausea

1-10%

Weight Loss

1-10%

Diarrhea

1-10%

Drug Not Working

0.1-1%

Fatigue

0.1-1%

Shortness of Breath

0.1-1%

Vomiting

0.1-1%

Dizziness

0.1-1%

FDA Warnings

Alogliptin And Pioglitazone

5 WARNINGS AND PRECAUTIONS Congestive heart failure: Fluid retention may occur and can exacerbate or lead to congestive heart failure
Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk
Consider the risks and benefits of OSENI prior to initiating treatment in patients at risk for heart failure
2 ) Hypersensitivity: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with alogliptin such as anaphylaxis, angioedema and severe cutaneous adverse reactions, including Stevens-Johnson syndrome

Pioglitazone Hydrochloride

5 WARNINGS AND PRECAUTIONS Congestive heart failure: Fluid retention may occur and can exacerbate or lead to congestive heart failure
Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk
1) Hypoglycemia: When used with insulin or an insulin secretagogue, a lower dose of the insulin or insulin secretagogue may be needed to reduce the risk of hypoglycemia
2) Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal

Clinical Trial Data

No head-to-head clinical studies found for Alogliptin And Pioglitazone vs Pioglitazone Hydrochloride.

Alogliptin And Pioglitazone vs Pioglitazone Hydrochloride: What You Should Know

Key Differences

Both Alogliptin And Pioglitazone and Pioglitazone Hydrochloride belong to the Thiazolidinedione class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Safety Considerations

Alogliptin And Pioglitazone carries 4 FDA warnings. Pioglitazone Hydrochloride carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

Alogliptin And Pioglitazone vs Pioglitazone→Pioglitazone vs Pioglitazone Hydrochloride→Alogliptin And Pioglitazone vs Rosiglitazone→Pioglitazone Hydrochloride vs Rosiglitazone→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

Alogliptin And Pioglitazone: DailyMed label · FAERS adverse events · ClinicalTrials.gov
Pioglitazone Hydrochloride: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

Alogliptin And Pioglitazone vs Pioglitazone Hydrochloride

Compare Alogliptin And Pioglitazone (Thiazolidinedione) and Pioglitazone Hydrochloride (Pioglitazone Hydrochloride), clinical data, side effects, and patient experiences.

Alogliptin And Pioglitazone

· Thiazolidinedione

How it works

12.1 Mechanism of Action OSENI combines two antihyperglycemic agents: alogliptin and pioglitazone. Alogliptin Increased concentrations of the incretin hormones such as glucagon-lik...

Approved for

1 INDICATIONS AND USAGE OSENI is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. OSENI is a combination of alogliptin

a dipeptidyl peptidase-4 inhibitor

and pioglitazone

a thiazolidinedione agonist of peroxisome proliferator receptor gamma

OralTablet

Pioglitazone Hydrochloride

Pioglitazone Hydrochloride · Thiazolidinedione

How it works

12.1 Mechanism of Action Pioglitazone is a thiazolidinedione that depends on the presence of insulin for its mechanism of action. Pioglitazone decreases insulin resistance in the p...

Approved for

14) Important Limitations of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. ( 1 )

OralTablet

Quick Comparison

Alogliptin And PioglitazonePioglitazone Hydrochloride

Drug Class

Thiazolidinedione

Route

Oral

Half-Life

N/A

FDA Approved

N/A

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

Alogliptin And Pioglitazone

Diarrhea

1-10%

Nausea

1-10%

Vomiting

1-10%

Rash

1-10%

General Unwellness

1-10%

Shortness of Breath

1-10%

Drug Not Working

1-10%

Dizziness

1-10%

Pioglitazone Hydrochloride

Nausea

1-10%

Weight Loss

1-10%

Diarrhea

1-10%

Drug Not Working

0.1-1%

Fatigue

0.1-1%

Shortness of Breath

0.1-1%

Vomiting

0.1-1%

Dizziness

0.1-1%

FDA Warnings

Alogliptin And Pioglitazone

5 WARNINGS AND PRECAUTIONS Congestive heart failure: Fluid retention may occur and can exacerbate or lead to congestive heart failure
Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk
Consider the risks and benefits of OSENI prior to initiating treatment in patients at risk for heart failure
2 ) Hypersensitivity: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with alogliptin such as anaphylaxis, angioedema and severe cutaneous adverse reactions, including Stevens-Johnson syndrome

Pioglitazone Hydrochloride

5 WARNINGS AND PRECAUTIONS Congestive heart failure: Fluid retention may occur and can exacerbate or lead to congestive heart failure
Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk
1) Hypoglycemia: When used with insulin or an insulin secretagogue, a lower dose of the insulin or insulin secretagogue may be needed to reduce the risk of hypoglycemia
2) Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal

Clinical Trial Data

No head-to-head clinical studies found for Alogliptin And Pioglitazone vs Pioglitazone Hydrochloride.

Alogliptin And Pioglitazone vs Pioglitazone Hydrochloride: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

Alogliptin And Pioglitazone: DailyMed label · FAERS adverse events · ClinicalTrials.gov
Pioglitazone Hydrochloride: DailyMed label · FAERS adverse events · ClinicalTrials.gov